UM

Browse/Search Results:  1-4 of 4 Help

Selected(0)Clear Items/Page:    Sort:
A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov Journal article
Yang, Jing, Kang, Heming, Lyu, Liyang, Xiong, Wei, Hu, Yuanjia. A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov[J]. Discover Oncology, 2023, 14(1), 151.
Authors:  Yang, Jing;  Kang, Heming;  Lyu, Liyang;  Xiong, Wei;  Hu, Yuanjia
Favorite | TC[WOS]:7 TC[Scopus]:7 | Submit date:2023/09/21
Bispecific Antibodies  Combination Therapy  Immuno-oncology Therapy  Kinase Inhibitors  Pd-1/pd-l1 Inhibitors  Targeted Therapy  
Current strategies for treating NSCLC: From biological mechanisms to clinical treatment Journal article
Li,Junnan, Kwok,Hang Fai. Current strategies for treating NSCLC: From biological mechanisms to clinical treatment[J]. Cancers, 2020, 12(6), 1587.
Authors:  Li,Junnan;  Kwok,Hang Fai
Favorite | TC[WOS]:27 TC[Scopus]:28  IF:4.5/4.9 | Submit date:2021/03/04
Combination Targeted Therapy  Drug Resistance Mechanism  Egfr Mutation  Lung Cancer  
Combination strategies using EGFR-TKi in NSCLC therapy: Learning from the gap between pre-clinical results and clinical outcomes Journal article
Yang,Zheng, Tam,Kin Yip. Combination strategies using EGFR-TKi in NSCLC therapy: Learning from the gap between pre-clinical results and clinical outcomes[J]. International Journal of Biological Sciences, 2018, 14(2), 204-216.
Authors:  Yang,Zheng;  Tam,Kin Yip
Favorite | TC[WOS]:74 TC[Scopus]:81  IF:8.2/8.3 | Submit date:2021/03/04
Chemotherapy  Combination  Egfr-tki  Immunotherapy  Nsclc  Targeted Therapy  
Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes Journal article
Yang, Zheng, Tam, Kin Yip. Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes[J]. INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2018, 14(2), 204-216.
Authors:  Yang, Zheng;  Tam, Kin Yip
Favorite | TC[WOS]:74 TC[Scopus]:81  IF:8.2/8.3 | Submit date:2018/10/30
Combination  Egfr-tki  Nsclc  Chemotherapy  Targeted Therapy  Immunotherapy